Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : KALEO INC
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Valeo Pharma Enters Into License Agreement with Kaléo for The Canadian Rights to Allerject®
Details : Under the Agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT (epinephrine) in Canada for an initial 10 years period.
Product Name : Allerject
Product Type : Hormone
Upfront Cash : Undisclosed
February 08, 2022
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : KALEO INC
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Desjardins Capital Markets
Deal Size : $10.0 million
Deal Type : Private Placement
Details : The net proceeds of the Offering and Concurrent Private Placement will be used to support commercial efforts related to the recently launched products (Redesca™, Enerzair®, and Atectura®).
Product Name : Redesca
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 24, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Desjardins Capital Markets
Deal Size : $10.0 million
Deal Type : Private Placement
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Group Purchasing Organizations
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the contracts, the GPOs have listed Redesca™ and Redesca HP™, Valeo’s leading low molecular weight heparin (“LMWH”) biosimilar, as well as three other hospital products (Amikacin, Ethacrynate Sodium and Benztropine), for a 3-...
Product Name : Redesca
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 13, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Group Purchasing Organizations
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ingenew Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients.
Product Name : Hesperco
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2021
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ingenew Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valeo Pharma’s Redesca™ Receives Positive Recommendation for Public Reimbursement in Quebec
Details : Redesca™ is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.
Product Name : Redesca
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valeo Pharma Announces Amikacin Approval in CANADA and U.S. Launch of Ethacrynate Sodium
Details : Valeo Pharma has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of Ethacrynate Sodium have commenced in the U.S. ...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valeo Pharma Files Natural Product License with Health Canada for Bioflavonoid Formulation, Hesperco
Details : Valeo Pharma has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.
Product Name : HesperCo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable